top
Please input keywords
Order
*Country
日本
アメリカ
中国
オーストラリア
シンガポール
イギリス
フランス
ドイツ
スイス
イタリア
カナダ
韓国
オランダ
ベルギー
スウェーデン
その他
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hSIGLEC8 mice
Strain Name


 C57BL/6-Gt(ROSA)26tm1(SIGLEC8)Bcgen/Bcgen 


Common Name 

B-hSIGLEC8 mice

Background  C57BL/6 Catalog number

 111149

Aliases 

SAF2; SIGLEC-8; SIGLEC8L


Protein expression analysis



SIGLEC8 expression analysis in homozygous B-hSIGLEC8 mice by flow cytometry. Blood and Peritoneal lavage fluid were collected from wild-type C57BL/6 mice (+/+) and homozygous B-hSIGLEC8 mice (H/H), and analyzed by FACS with anti-SIGLEC8 antibody. Human SIGLEC8 was detectable in Eosinophils(88%, mSiglec-F+,mCD11c-) and mast cells (99.8%, mFcεRIα+,mCD117(c-kit)+,CD11b-) in homozygous B-hSIGLEC8 mice.


Eosinophils and mast cells in B-hSIGLEC8 mice bind to anti-human SIGLEC8 antibody


from clipboard

Analysis of eosinophils and mast cells of B-hSIGLEC8 mice by flow cytometry. Eosinophils and Peritoneal lavage-mast cells isolated from wild-type C57BL/6 mice (+/+) and B-hSIGLEC8 mice (H/H). Flow cytometry analysis was performed to assess human SIGLEC8 expression using the Benchmark antibody Lirentelimab (in house). Eosinophils were gated from mSiglec-F+,mCD11c- population and mast cells were gated from CD45+mFcεRIα+,mCD117(c-kit)+CD11b- population. Lirentelimab was exclusively binding to SIGLEC8 in homozygous B-hSIGLEC8 mice but not wild-type mice.


The number of BALF immune cells in mouse asthma model


from clipboard


The number of BALF Immune cells in mouse asthma model. BALF Immune cells were isolated from B-hSIGLEC8 mice (n=6). The number of eosinophils was analyzed by flow cytometry under the treatment of PBS or lirentelimab (in house). After treatment of lirentelimab, the expression level of inflammatory cells was lower than the positive control in homozygous B-hSIGLEC8 mice.

In vivo efficacy of anti-human SIGLEC8 antibody

from clipboard


H&E staining in asthma-like model in B-hSIGLEC8 mice. (A) Lung tissues were collected from at the study end point. H&E staining results showed that the lung tissues from B-hSIGLEC8 mice exposed to PBS aerosols did not show any inflammation. OVA exposure resulted in a significant increase in peribronchial and perivascular inflammation in B-hSIGLEC8 mice. (B) A significantly reduction in eosinophils infiltration was observed in mice treated with lirentelimab (in house). 
Note: The lirentelimab in the treatment model group were administered via intratracheal aerosolization.